An Acute Onset of Paraparesis in 65 Years Old Croatian Woman - A Case Report
DOI:
https://doi.org/10.61788/njn.v2i17.11Keywords:
neuromyelitis optica (NMO), Devic`s disease, case report, treatmentAbstract
Neuromyelitis optica (NMO, Devic`s disease) is a rare inflammatory, demyelinating disease of the central nervous system that predominantly affects the spinal cord and optic nerves. Seropositivity for NMO-IgG (aquaporin 4 antybodies) and longitudinally extensive spinal cord lesions (3 or more segments) are characteristics of NMO. We described a 65-year old woman with an acute onset of paraparesis that was not recognized as NMO at the beginning. The diagnosis was made three months later when she was readmitted because of the relapse. Despite the treatment with high doses of methylprednisolone, plasmapheresis and immunoglobulins her condition stayed unchanged - she was paraplegic and incontinent.
References
Wingerchuk D. M., Lennon V. A., Lucchinetti C. F., Pittock S. J., Weinshenker B. G. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
Lennon V. A., Wingerchuk D. M., Kryzer T. J. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
Wingerchuk D. M., Banwell B., Bennett J. L., Cabre P., Carroll W., Chitnis T., et al. 2015. International consensus criteria for neuromyelitis optica spectrum disorders. Neurology 85:177-189.
Pandit L., Asgari N., Apiwattanakul M., Palace J., Paul F., Leite M. I., et al. 2015. Demographic and clinical features of neuromyelitis optica: a review. Mult. Scler. 21:845-853.
Kim W., Kim S. H., Kim H. J. New Insights into Neuromyelitis Optica. J Clin Neurol 2011;7:115-127.
Wingerchuk D. M., Weinshenker B. G. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60:848-53.
Trebst C., Jarius S., Berthele A., Paul F., Schippling S., Wildemann B., et al. (2014) Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261: 1-16.
Kim S. H., Jeong I. H., Hyun J. W. et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015;72(9):989-995.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 National Association of Neurologists

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



